Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2023 Planned End Date changed from 1 Aug 2024 to 1 Sep 2024.
- 29 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Sep 2023.
- 31 Aug 2023 Status changed from recruiting to active, no longer recruiting.